Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| NCT ID | NCT03962465 |
| Title | Phase I Study of Inotuzumab With Augmented BFM Re-Induction for Patients With Relapsed/Refractory B-cell ALL (ALL-001) |
| Acronym | ALL-001 |
| Recruitment | Active, not recruiting |
| Gender | both |
| Phase | Phase I |
| Variant Requirements | No |
| Sponsors | University of Virginia |
| Indications | |
| Therapies | |
| Age Groups: | adult | senior |
| Covered Countries | USA |
| Facility | Status | City | State | Zip | Country | Details |
|---|---|---|---|---|---|---|
| Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | 37232 | United States | Details | |
| University of Virginia | Charlottesville | Virginia | 22908 | United States | Details | |
| VCU Massey Cancer Center | Richmond | Virginia | 23298 | United States | Details | |
| University of Wisconsin | Madison | Wisconsin | 53792 | United States | Details |